ZIMLAB Stock Overview
ZIM Laboratories Limited develops, manufactures, and supplies generic pharmaceutical and nutraceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ZIM Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹121.95 |
| 52 Week High | ₹152.70 |
| 52 Week Low | ₹73.95 |
| Beta | 0.59 |
| 1 Month Change | 22.38% |
| 3 Month Change | 11.88% |
| 1 Year Change | 53.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.75% |
Recent News & Updates
Shareholder Returns
| ZIMLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 27.3% | -0.1% | 1.8% |
| 1Y | 53.5% | 55.9% | 46.4% |
Return vs Industry: ZIMLAB underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: ZIMLAB exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| ZIMLAB volatility | |
|---|---|
| ZIMLAB Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ZIMLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: ZIMLAB's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 525 | Anwar Daud | www.zimlab.in |
ZIM Laboratories Limited develops, manufactures, and supplies generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations using modified release patterns in the oral solid dosage forms, such as granules, pellets, taste-masked powders, suspensions, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, CNS, antibiotics, anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements.
ZIM Laboratories Limited Fundamentals Summary
| ZIMLAB fundamental statistics | |
|---|---|
| Market cap | ₹5.89b |
| Earnings (TTM) | ₹163.97m |
| Revenue (TTM) | ₹3.55b |
35.9x
P/E Ratio1.7x
P/S RatioIs ZIMLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZIMLAB income statement (TTM) | |
|---|---|
| Revenue | ₹3.55b |
| Cost of Revenue | ₹1.73b |
| Gross Profit | ₹1.82b |
| Other Expenses | ₹1.65b |
| Earnings | ₹163.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.37 |
| Gross Margin | 51.22% |
| Net Profit Margin | 4.62% |
| Debt/Equity Ratio | 27.6% |
How did ZIMLAB perform over the long term?
See historical performance and comparison